Santa Monica, CA, Feb. 05, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company has appointed Mr. John Kowalski as Vice President of Sales. Mr. […]
Tag: BioSig
BioSig Technologies To Commence First–in-Human Studies at Mayo Clinic
Santa Monica, CA, Dec. 06, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has signed an agreement with Mayo Clinic to […]
Medical Leaders Join BioSig Clinical Advisory Board
Santa Monica, CA, Nov. 28, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company formed a Clinical Advisory Board to complement existing scientific […]
BioSig Technologies Signs Agreement with Texas Cardiac Arrhythmia Institute for First–in-Human Studies
Santa Monica, CA, Nov. 27, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has signed an agreement with Texas Cardiac Arrhythmia […]
BioSig Technologies Reinvests in Lafayette College’s InternShift Progam
Santa Monica, CA, Nov. 20, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company’s Founder, Chairman & CEO Kenneth Londoner is making […]
BioSig Technologies Announces New Research Program with Mayo Clinic
Santa Monica, CA, Nov. 13, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company entered into a new advanced research agreement with Mayo […]
BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018
Santa Monica, CA, Nov. 12, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today its Founder, Chairman & CEO […]
BioSig Technologies to Present at the 4th Annual Dawson James Small Cap Growth Conference
Santa Monica, CA, Oct. 29, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that it will be presenting […]
BioSig Technologies Retains Gilmartin Group for Investor Relations
Santa Monica, CA, Sept. 24, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ:BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that it has retained Gilmartin Group for strategic investor relations […]
BioSig Technologies to Commence Trading on the Nasdaq
Santa Monica, CA, Sept. 19, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB:BSGM, OTCQB:BSGMD), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced that its shares of common stock have been approved for […]